Format

Send to

Choose Destination
Contrib Nephrol. 2011;171:208-212. doi: 10.1159/000327326. Epub 2011 May 23.

Acute kidney injury biomarkers and endpoints for clinical trials.

Author information

1
UCD Catherine Mc Auley Education and Research Centre, Dublin, Ireland.

Abstract

Acute kidney injury (AKI) is associated with a heavy burden of morbidity and mortality, despite advances in intensive care and the management of high-risk patients. Numerous clinical trials have failed to ameliorate the outcomes of AKI. The proposal and validation of standardized definitions and staging criteria for AKI has been an important step in improving the conduct of clinical trials in this population. Similarly, a multidisciplinary dialogue is making progress towards standardization of the clinical trial endpoints to prove efficacy and effectiveness in AKI research. Taken together with the increasing availability of timely, sensitive, and specific novel biomarkers of kidney damage, we are poised to use these tools to conduct successful clinical trials of agents for the prevention and treatment of this devastating clinical syndrome.

PMID:
21625113
DOI:
10.1159/000327326
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center